Human Recombinant Insulin Market Size
| Study Period | 2018 - 2029 |
| Market Size (2024) | USD 28.47 Billion |
| Market Size (2029) | USD 32.20 Billion |
| CAGR (2024 - 2029) | 2.90 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Human Recombinant Insulin Market Analysis
The Human Recombinant Insulin Market size is estimated at USD 28.47 billion in 2024, and is expected to reach USD 32.20 billion by 2029, growing at a CAGR of greater than 2.9% during the forecast period (2024-2029).
COVID-19 is expected to drive the growth of the market during the forecast period. The increased risk for diabetes patients during the COVID-19 outbreak is expected to drive the demand for the human recombinant insulin market. For instance, the article titled ' COVID-19 and Diabetes' published in December 2020 mentioned that about 25% of people who visited the hospital with severe COVID-19 infections had diabetes. Additionally, the article titled ' COVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course' published in June 2021 mentioned that Patients with diabetes are known to have an increased risk of infections particularly respiratory tract infects such as SARS-CoV-2. Thus, the outbreak of COVID-19 is expected to drive the growth of the market during the pandemic period.
The factors such as the increasing prevalence of diabetes across the world are expected to drive the growth of the market during the forecats period. Diabetes is one of the most malignant diseases of the 21st century. According to the World Health Organization, it has been predicted that diabetes is likely to be the seventh most leading cause of death by 2030.
Furthermore, obesity is the most potent factor for Type 2 diabetes, which accounts for 80-85% of the overall risk of developing Type 2 diabetes. In April 2022, United States National Center for Chronic Disease Prevention and Health Promotion updated its article on physical inactivity and estimated that the reduction in physical activity is one of the major factors causing diseases such as type II diabetes. Hence, due to the exponential rise in the prevalence of diabetes, there is an urgent demand for establishing effective diabetes therapy in countries, which are burdened by inadequate health care budgets, malnutrition, and infectious diseases which is augmenting the demand for human recombinant insulin and the market is majorly driven by the same factor.
Human Recombinant Insulin Market Trends
Humulin is Expected to Witness a Healthy CAGR Over the Forecast Period
Humulin is a polypeptide hormone structurally identical to human insulin synthesized through rDNA technology in a non-disease-producing laboratory strain of E. coli bacteria. Humulin was licensed to Eli Lilly and became the first marketable product created through recombinant DNA technology. The increasing health care expenditure for humulin is expected to drive the growth of the studied segment. For instance, the article titled ' Insulin Out-of-Pocket Costs in Medicare Part D," published in July 2022, mentioned that the average out-of-pocket spending by Medicare Part D enrollees per Humulin R U-500 was USD 116. Humulin N is formulated to have a slower onset of action than regular insulin and a longer duration of activity (slightly less than 24 hours). Thus, the better accessibility of Humulin is resulting in increased demand for the same.
However, some of the adverse reactions related to the Humulin R U-100 are restraining the growth of the Humulin. For instance, hyperglycemia, diabetic ketoacidosis, or hyperosmolar coma may develop if the patient takes less Humulin R U-100 than needed to control blood glucose levels.
North America Holds a Significant Share of the Market During the Forecast Period
North America is expected to hold a major share of the market's growth during the forecast period. This is mainly due to the increasing prevalence of diabetes in this region and the increasing market players' activities. Diabetes ranks among the fastest-growing chronic diseases in the United States. About 1.75 million US citizens are diagnosed with diabetes every year. The country also has the highest obesity population, which is a prominent cause of type-2 diabetes. However, about 28% of Americans are undiagnosed, and another 86% of American adults have blood glucose levels that greatly increase their risk of developing diabetes in the next several years. Over the last two decades, the number of adults diagnosed with diabetes has more than doubled as the American population has aged and become more overweight or obese. Owing to this rise in the diabetic population in this country, there is a growing demand for diabetes therapeutics, which is augmenting the growth of the market studied in the United States.
Additionally, increasing product launches are also expected to drive the growth of the market during the forecast period. For instance, in January 2021, rBio, a United States-based early-stage synthetic biology company, started using rDNA technology to synthesize the production of synthetic insulin, potentially lowering the cost of insulin by 30%, as well as identify other prescription drugs that can be manufactured by manipulating microorganisms to express peptide hormones.
Thus, the above-mentioned factors are expected to drive the growth of the market during the forecast period in this region.
Human Recombinant Insulin Industry Overview
The human recombinant insulin market studied is consolidated, as there are few companies that are dominating the market currently. Some of the key players that have a considerable share of this market include Eli Lilly and Company, Novo Nordisk, and Sanofi S.A., among others.
Human Recombinant Insulin Market Leaders
-
Novo Nordisk A/S
-
Eli Lilly and Company
-
Sanofi S.A.
-
Biocon
-
Zhuhai United Laboratories Co., Ltd.
*Disclaimer: Major Players sorted in no particular order
Human Recombinant Insulin Market News
- April 2022: Biocon Biologics received a positive European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) opinion for Inpremzi, a biosimilar human insulin for IV infusions.
- April 2022: Biocon Biologics in Malaysia was awarded a three-year contract, valued at USD 90 million, for its recombinant human insulin brand Insugen by the Ministry of Health, Malaysia.
Human Recombinant Insulin Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Buyers/Consumers
- 4.4.2 Bargaining Power of Suppliers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Drug
- 5.1.1 Short-acting Human Insulin
- 5.1.2 Intermediate-acting Human Insulin
- 5.1.3 Premixed Human Insulin
-
5.2 Brand
- 5.2.1 Insuman
- 5.2.2 Humulin
- 5.2.3 Novolin
- 5.2.4 Other Brands
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Australia
- 5.3.3.7 Vietnam
- 5.3.3.8 Malaysia
- 5.3.3.9 Indonesia
- 5.3.3.10 Philippines
- 5.3.3.11 Thailand
- 5.3.3.12 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 Saudi Arabia
- 5.3.4.2 Iran
- 5.3.4.3 Egypt
- 5.3.4.4 Oman
- 5.3.4.5 South Africa
- 5.3.4.6 Rest of Middle East and Africa
- 5.3.5 Latin America
- 5.3.5.1 Mexico
- 5.3.5.2 Brazil
- 5.3.5.3 Rest of Latin America
6. Market Indicators
- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
-
7.1 Company Profiles
- 7.1.1 Biocon
- 7.1.2 Bioton S.A.
- 7.1.3 Eli Lilly and Company
- 7.1.4 Gan & Lee Pharmaceuticals, Ltd
- 7.1.5 Julphar Gulf Pharmaceutical Industries
- 7.1.6 Novo Nordisk A/S
- 7.1.7 Sanofi S.A.
- 7.1.8 Zhuhai United Laboratories Co., Ltd
- *List Not Exhaustive
- 7.2 Company Share Analysis
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityHuman Recombinant Insulin Industry Segmentation
As per the scope of the report, recombinant human insulin has replaced animal insulin and animal-based semi synthetic human insulin, which are available in sufficient quantities and at affordable prices, in order to provide global access to insulin therapy. The human recombinant insulin market is segmented by drug (short-acting human insulin, intermediate-acting human insulin, and premixed human insulin), brand (Insuman, Humulin, Novolin, and other brands), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America). The market report also covers the estimated market sizes and trends for different countries across major regions and globally. The report offers the value (in USD) and volume (in unit mL) for the above segments. The report will provide a segment-wise breakdown (value and volume) for all the countries covered under the table of contents.
| Drug | Short-acting Human Insulin | |
| Intermediate-acting Human Insulin | ||
| Premixed Human Insulin | ||
| Brand | Insuman | |
| Humulin | ||
| Novolin | ||
| Other Brands | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Australia | ||
| Vietnam | ||
| Malaysia | ||
| Indonesia | ||
| Philippines | ||
| Thailand | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | Saudi Arabia |
| Iran | ||
| Egypt | ||
| Oman | ||
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | Latin America | Mexico |
| Brazil | ||
| Rest of Latin America |
Human Recombinant Insulin Market Research FAQs
How big is the Human Recombinant Insulin Market?
The Human Recombinant Insulin Market size is expected to reach USD 28.47 billion in 2024 and grow at a CAGR of greater than 2.9% to reach USD 32.20 billion by 2029.
What is the current Human Recombinant Insulin Market size?
In 2024, the Human Recombinant Insulin Market size is expected to reach USD 28.47 billion.
Who are the key players in Human Recombinant Insulin Market?
Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Biocon and Zhuhai United Laboratories Co., Ltd. are the major companies operating in the Human Recombinant Insulin Market.
Which is the fastest growing region in Human Recombinant Insulin Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Human Recombinant Insulin Market?
In 2024, the North America accounts for the largest market share in Human Recombinant Insulin Market.
What years does this Human Recombinant Insulin Market cover, and what was the market size in 2023?
In 2023, the Human Recombinant Insulin Market size was estimated at USD 27.67 billion. The report covers the Human Recombinant Insulin Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Human Recombinant Insulin Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Human Recombinant Insulin Industry Report
Statistics for the 2024 Human Recombinant Insulin market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Human Recombinant Insulin analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
